This is a summary. To read the whole story subscribe to BostonGlobe.com
Shares of Epizyme Inc. vaulted 75.5 percent Tuesday after the Cambridge biotechnology startup disclosed that an experimental cancer drug had performed well enough to earn a payout from the company’s partner, Celgene Corp.
News of the $25 million “proof of concept” milestone payment from Celgene, based in Summit, N.J., lifted Epizyme’s stock by $15.49 a share to $35.99 on the Nasdaq exchange.
Epizyme’s drug candidate, called EPZ-5676, is designed to treat genetically defined cancers.
The company said it had also earned a $4 million payment from the British pharmaceutical giant GlaxoSmithKline PLC for its work on a separate targeted cancer therapy.
A pioneer in the emerging field of “epigenetics,” Epizyme went public in June.